COMPARISON OF THE ORAL ANGIOTENSIN-II RECEPTOR ANTAGONIST UP-269-6 OR ENALAPRIL 20 MG ON BLOOD-PRESSURE AND NEUROHORMONAL EFFECTS IN SALT-DEPLETE MAN

被引:15
作者
MCINTYRE, M
MACFADYEN, RJ
MEREDITH, PA
MENARD, J
BRUNNER, HR
INSUASTY, J
REID, JL
机构
[1] UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND
[2] HOP BROUSSAIS,CTR INVEST CLIN,PARIS,FRANCE
[3] UNIV LAUSANNE HOSP,DIV HYPERTENS,LAUSANNE,SWITZERLAND
[4] UPSA LABS,RUEIL MALMAISON,FRANCE
关键词
ANGIOTENSIN RECEPTOR ANTAGONIST; UP269-6; ENALAPRIL; BLOOD PRESSURE REDUCTION; RENIN; ANGIOTENSIN SYSTEM BLOCKADE; HORMONES;
D O I
10.1097/00005344-199506000-00020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We compared the response of the oral angiotensin II (Ang II) receptor antagonist (ARA) UP 269-6 with an angiotensin converting enzyme inhibitor (ACEI) enalapril 20 mg or placebo, during salt depletion in normal men. We also evaluated safety and tolerability. Sixteen healthy, normotensive male volunteers followed a standardised salt-depletion regimen for 3 days before each study day. Seven different doses of UP 269-6 (5, 10, 20, 40, 80, 120 and 180 mg) were administered double blind in a four-panel dose escalation, with enalapril and placebo randomised within each panel. Supine and erect blood pressure (BP) and heart rate (HR); serum and urinary electrolytes; plasma active renin (PAR), aldosterone, and Ang II were measured at intervals. Urinary electrolytes and aldosterone were measured for the 24 h before dosing and for 24 h after dosing. Dizziness and light-headedness on standing were reported after UP 269-6 at higher doses. Enalapril caused one episode of symptomatic postural hypotension. No other drug-related adverse events (AE) were noted. There was a dose-related decrease in supine and erect systolic and diastolic BP (SEP, DBP) with UP 269-6 at greater than or equal to 40 mg, with no change in HR. Based on the maximal decrease in mean arterial pressure (MAP), UP 269-6 at 180 mg had an effect largely comparable to that of enalapril 20 mg. There was a dose-related increase in PAR with UP 269-6. Although this was greater with UP 269-6 180 mg than with enalapril, serum and 24-h urinary aldosterone suppression was greater with enalapril than with any dose of UP 269-6. There was a dose-related increase in Ang II, with the expected decrease after enalapril. Our results indicate a clear BP and hormonal dose response relation for UP 269-6. The BP-lowering effect is observed starting with the 40-mg dose. Based on the maximal decrease in MAP, UP 269-6 180 mg is largely comparable to enalapril 20 mg.
引用
收藏
页码:994 / 1000
页数:7
相关论文
共 26 条
[1]   RENIN RELATIONSHIPS IN CONGESTIVE CARDIAC FAILURE, TREATED AND UNTREATED [J].
BROWN, JJ ;
DAVIES, DL ;
JOHNSON, VW ;
LEVER, AF ;
ROBERTSON, JI .
AMERICAN HEART JOURNAL, 1970, 80 (03) :329-+
[2]   NOMENCLATURE FOR ANGIOTENSIN RECEPTORS - A REPORT OF THE NOMENCLATURE-COMMITTEE OF THE COUNCIL-FOR-HIGH-BLOOD-PRESSURE-RESEARCH [J].
BUMPUS, FM ;
CATT, KJ ;
CHIU, AT ;
DEGASPARO, M ;
GOODFRIEND, T ;
HUSAIN, A ;
PEACH, MJ ;
TAYLOR, DG ;
TIMMERMANS, PBMWM .
HYPERTENSION, 1991, 17 (05) :720-721
[3]   ORAL-ADMINISTRATION OF DUP-753, A SPECIFIC ANGIOTENSIN-II RECEPTOR ANTAGONIST, TO NORMAL-MALE VOLUNTEERS - INHIBITION OF PRESSOR-RESPONSE TO EXOGENOUS ANGIOTENSIN-I AND ANGIOTENSIN-II [J].
CHRISTEN, Y ;
WAEBER, B ;
NUSSBERGER, J ;
PORCHET, M ;
BORLAND, RM ;
LEE, RJ ;
MAGGON, K ;
SHUM, L ;
TIMMERMANS, PBMWM ;
BRUNNER, HR .
CIRCULATION, 1991, 83 (04) :1333-1342
[4]   DOSE-RESPONSE RELATIONSHIPS FOLLOWING ORAL-ADMINISTRATION OF DUP 753 TO NORMAL HUMANS [J].
CHRISTEN, Y ;
WAEBER, B ;
NUSSBERGER, J ;
LEE, RJ ;
TIMMERMANS, PBMWM ;
BRUNNER, HR .
AMERICAN JOURNAL OF HYPERTENSION, 1991, 4 (04) :S350-S353
[5]   SEVERE HYPOTENSION AFTER 1ST DOSE OF ENALAPRIL IN HEART-FAILURE [J].
CLELAND, JGF ;
DARGIE, HJ ;
MCALPINE, H ;
BALL, SG ;
MORTON, JJ ;
ROBERTSON, JIS ;
FORD, I .
BRITISH MEDICAL JOURNAL, 1985, 291 (6505) :1309-1312
[6]   AN OVERVIEW OF THE CLINICAL-PHARMACOLOGY OF ENALAPRIL [J].
DAVIES, RO ;
GOMEZ, HJ ;
IRVIN, JD ;
WALKER, JF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 :S215-S229
[7]  
DOIG JK, 1993, J CARDIOVASC PHARM, V21, P732, DOI 10.1097/00005344-199305000-00007
[8]  
DOIG JK, 1995, IN PRESS J CARDIOVAS
[9]   FACTORS RELATED TO 1ST DOSE HYPOTENSIVE EFFECT OF CAPTOPRIL - PREDICTION AND TREATMENT [J].
HODSMAN, GP ;
ISLES, CG ;
MURRAY, GD ;
USHERWOOD, TP ;
WEBB, DJ ;
ROBERTSON, JIS .
BRITISH MEDICAL JOURNAL, 1983, 286 (6368) :832-834
[10]   COMPARISON OF THE ANGIOTENSIN-II ANTAGONIST UP269-6 WITH THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ENALAPRIL IN NORMOTENSIVE VOLUNTEERS CHALLENGED WITH ANGIOTENSIN-I [J].
INGLESSIS, N ;
NUSSBERGER, J ;
HAGMANN, M ;
HIESSEPROVOST, O ;
INSUASTY, J ;
REID, J ;
MENARD, J ;
BRUNNER, HR .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 (06) :986-993